## Abstract Fortyβeight patients with newlyβdiagnosed testicular seminomas were followed for a mean of 7 years after treatment. At the time of diagnosis, seminoma was confined to testis in 74% (36) and was metastatic to retroperitoneal lymph nodes in 15% (7) and to distant nodal sites or parenchyma
Second cancer in patients treated for testicular seminoma
β Scribed by Moshe Stein; Norman Loberant; Michaela Laviov; Gaddy Rennert; Jesse Lachter; Abraham Kuten
- Publisher
- John Wiley and Sons
- Year
- 1992
- Tongue
- English
- Weight
- 388 KB
- Volume
- 49
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
β¦ Synopsis
The exact risk of developing a second primary cancer following radiotherapy for testicular seminoma is not known. At the Northern Israel Oncology Center, between the years 1968-1988, 75 patients with early stage (1,IIA) testicular seminoma were treated by orchiectomy followed by radiation therapy. The overall 10-and 20-year survival probability was 95% and 9096, respectively. Eight patients ( I 1 %) developed nine second cancers, with a cumulative rate of one case per 1,000 years of follow-up. The second primary cancers were: two bronchogenic carcinomas, one contralateral seminoma, one thymoma, one papillary carcinoma of the thyroid, one carcinoma of the stomach, one transitional cell carcinoma of the urinary bladder, one carcinoma of the colon, and one malignant melanoma. Three of these tumors developed within the irradiated field. Five of these eight patients are alive with no evidence of recurrent cancer. We conclude that patients treated for seminoma have an increased risk of developing a second cancer. There is a need for greater awareness of this possibility. The overall prognosis remains favorable.
π SIMILAR VOLUMES
The success of combination chemotherapy in treating advanced metastatic germ cell tumors has led to new challenges for the genitourinary oncologic surgeon in the peri-operative care of patients. Surgery remains an integral part of the management of patients with advanced germ cell tumors. Retroperit
Today, the standard treatment for patients with clinical Stage I non-seminomatous testicular germ cell tumors (NSTGCT) following orchidectomy is either primary retroperitoneal lymph node dissection (RPLND) or close surveillance with cisplatin-based polychemotherapy in case of a relapse. Both treatme